



SDI Review Form 1.6

Journal Name:	British Journal of Medicine and Medical Research
Manuscript Number:	Ms_BJMMR_24673
Title of the Manuscript:	A comparison of rheumatoid arthritis patients in Kuwait with other populations: results from the KRRD registry
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



SDI Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<u>Compulsory</u> REVISION comments	<p>(1) Line 27: The reference for ACR criteria should be cited</p> <p>(2) Line 93: The word "ACPA Negative" has to be added in Table 2-column 1</p> <p>(3) Line 177: The statement of "genetic heritability was roughly 605 (ref 43)" should be further explained.</p> <p>(4) Line 190: What means that "share epitope for ACPA between smoking and RA"?</p>	<p>Reference added.</p> <p>ACPA negative added.</p> <p>It should be 60% not 605 (corrected).</p> <p>Explained in more details in the text.</p>
<u>Minor</u> REVISION comments	<p>(1) Line 52: The abbreviation of ACPA is derived from "anti-citrullinated peptide or protein antibody". The word "cyclic" seems not necessary.</p> <p>(2) Line 54: "HEp-2" but not hep2 cells</p> <p>(3) Line 167 Table 5: The rate of CAD in Kuwait general population is N/A. However, it seems not different from RA population as described in the text. It is necessary to add the number in the Table.</p>	<p>ACPA corrected throughout the text and abstract.</p> <p>HEp-2 corrected.</p> <p>Unfortunately, there is no available data on the prevalence of CAD in Kuwait general population. Apparently it was misunderstood when I mentioned it in the text so I rephrased it in the text to make it more clear for the reader.</p>
<u>Optional/General</u> comments	The authors described the prevalence of serological findings (RFs, ACPA, RFs+ACPAs) and common comorbidities in KRRD from 2023-2015 vs. general Kuwait and other non-Kuwait RA populations in western countries. Some unique findings are observed.	Thank you